News
Evolva business update: Continued good business momentum
Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.
Kuros Biosciences Appoints Chris Fair as Chief Operating Officer
Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate
Tavneos® erhält Swissmedic-Zulassung für die Behandlung ANCA-assoziierter Vaskulitis
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) hat heute die Zulassung von Tavneos® durch die Schweizerische Zulassungs- und Aufsichtsbehörde für Arzneimittel und Medizinprodukte Swissmedic
Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago
Kuros Biosciences announces successful CHF 6.0 million private placement
Relief Reports Half-Year 2022 Results and Provides Corporate Update
Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum
Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Lonza and Touchlight collaborate on end-to-end mRNA offering
GeNeuro : Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein (HERV-K/HML-2 ENV) and the Rationale for Targeted Therapy With Specific Antibody
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic
DGAP-News: BB BIOTECH AG: Moderna was just the beginning
Evolva with record half-yearly sales and new mid-term plan
Relief Therapeutics files registration statement on form F-1 with the U.S. Securities and Exchange Commission
Sonova to enable fully immersive conversations in virtually any situation with new Lumity platform
Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones
CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the
VFMCRP announces U.S. Court upholds validity of Velphoro® patent
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRP’s favor regarding U.S. patent no. 9,561,251
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. announce tentative settlement of pending litigation
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic
Sonova to accelerate expansion of direct consumer access in Chinese market with acquisition of leading network of clinics
Tavneos® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is pleased to announce that England’s National Institute for Health and Care Excellence (NICE) has recommended Tavneos® in combination with a
Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access